index

MERCK DANS L'ACTUALITÉ

DERNIÈRES NOUVELLES

Le 11 septembre 2018
Renseignements importants concernant le contraceptif oral MARVELON^® 28 (comprimés de désogestrel et d’éthinylestradiol) – Absence des étiquettes autocollantes indiquant les jours de la semaine

Le 11 septembre 2018
Santé Canada approuve STROMECTOL^™ (ivermectine), un produit de Merck, pour le traitement de la strongyloïdose intestinale et de l’onchocercose

Le 22 août 2018
Ajout de RENFLEXIS^MC (infliximab pour injection) à la liste du régime provincial d’assurance médicaments de la Colombie-Britannique pour toutes les indications approuvées

20 juin 2017
Important financement prévu dans le secteur des sciences de la vie de l’Alberta

25 mai 2017
Merck Canada Inc. accorde un financement de 2,6 millions de dollars à des chercheurs spécialisés dans le domaine des populations autochtones pour soutenir un programme de santé maternelle et infantile au sein de populations autochtones en Ontario

8 mai 2017
Récentes inondations : alerte aux employés de Merck Canada Inc.

21 Avril 2017
Merck tient à féliciter l’Organisation mondiale de la Santé (OMS) pour la Semaine mondiale de la vaccination

Ce site Web est conçu pour permettre aux représentants des médias d'accéder rapidement et facilement à de l'information récente sur Merck. Pour obtenir des renseignements supplémentaires, veuillez consulter 'À notre sujet'.

Personne-ressource pour les médias

Dominique Quirion

Affaires corporatives et communications sur les produits

514-428-3469

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.